Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie

References

1. Aguzzi A., Glatzel M., Montrasio F., Prinz M., Heppner F. L. 2001; Interventional strategies against prion diseases. Nat Rev Neurosci 2:745–749 [CrossRef]
   [Google Scholar]
2. Barret A., Tagliavini F., Forloni G. 13 other authors 2003; Evaluation of quinacrine treatment for prion diseases. J Virol 3:8462–8469
   [Google Scholar]
3. Béranger F., Mangé A., Solassol J., Lehmann S. 2001; Cell culture models of transmissible spongiform encephalopathies. Biochem Biophys Res Commun 289:311–316 [CrossRef]
   [Google Scholar]
4. Beringue V., Lamoury F., Adjou K. T., Maignien T., Demoy M., Couvreur P., Dormont D. 2000 Pharmacological manipulation of early PrP^res accumulation in the spleen of scrapie-infected mice Arch Virol Suppl;39–56
   [Google Scholar]
5. Bosque P. J., Prusiner S. B. 2000; Cultured cell sublines highly susceptible to prion infection. J Virol 74:4377–4386 [CrossRef]
   [Google Scholar]
6. Bourne N., Stanberry L. R., Kern E. R., Holan G., Matthews B., Bernstein D. I. 2000; Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother 44:2471–2474 [CrossRef]
   [Google Scholar]
7. Brown P. 2002; Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58:1720–1725 [CrossRef]
   [Google Scholar]
8. Bruce M. E., Brown K. L., Mabbott N. A., Farquhar C. F., Jeffrey M. 2000; Follicular dendritic cells in TSE pathogenesis. Immunol Today 21:442–446 [CrossRef]
   [Google Scholar]
9. Caughey W. S., Raymond L. D., Horiuchi M., Caughey B. 1998; Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A 95:12117–12122 [CrossRef]
   [Google Scholar]
10. Collinge J. 2001; Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519–550 [CrossRef]
    [Google Scholar]
11. Demart S., Fournier J. G., Creminon C. 7 other authors 1999; New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 265:652–657 [CrossRef]
    [Google Scholar]
12. Gilch S., Winklhofer K. F., Groschup M. H. 7 other authors 2001; Intracellular re-routing of prion protein prevents propagation of PrP^Sc and delays onset of prion disease. EMBO J 20:3957–3966 [CrossRef]
    [Google Scholar]
13. Heppner F. L., Musahl C., Arrighi I., Klein M. A., Rulicke T., Oesch B., Zinkernagel R. M., Kalinke U., Aguzzi A. 2001; Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294:178–182 [CrossRef]
    [Google Scholar]
14. Klohn P. C., Stoltze L., Flechsig E., Enari M., Weissmann C. 2003; A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci U S A 100:11666–11671 [CrossRef]
    [Google Scholar]
15. Korth C., May B. C., Cohen F. E., Prusiner S. B. 2001; Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836–9841 [CrossRef]
    [Google Scholar]
16. Lasmezas C. I., Cesbron J. Y., Deslys J. P., Demaimay R., Adjou K. T., Rioux R., Lemaire C., Locht C., Dormont D. 1996; Immune system-dependent and -independent replication of the scrapie agent. J Virol 70:1292–1295
    [Google Scholar]
17. Lehmann S., Harris D. A. 1995; A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. J Biol Chem 270:24589–24597 [CrossRef]
    [Google Scholar]
18. Lehmann S., Laude H., Harris D. A., Carp C., Vilette D., Katamine S., Madec J. Y., Nishida N. 2001; Ex vivo transmission of mouse adapted prion strains to N2a and GT1-7 cell lines. In Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics pp  679–686 Edited by Iqbal K., Sisodia S. S., Wingblad B. Chichester, UK: Wiley;
    [Google Scholar]
19. Loup C., Zanta M. A., Caminade A. M., Majoral J. P., Meunier B. 1999; Preparation of water-soluble cationic phosphorus-containing dendrimers as DNA transfecting agents. Chem Eur J 5:3644–3650 [CrossRef]
    [Google Scholar]
20. Mabbott N. A., Young J., McConnell I., Bruce M. E. 2003; Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J Virol 77:6845–6854 [CrossRef]
    [Google Scholar]
21. Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J. W., Meijer E. W., Paulus W., Duncan R. 2000; Dendrimers: relationship between structure and biocompatibility in vitro , and preliminary studies on the biodistribution of ¹²⁵I-labelled polyamidoamine dendrimers in vivo . J Control Release 65:133–148 [CrossRef]
    [Google Scholar]
22. Mangé A., Nishida N., Milhavet O., McMahon H. E. M., Casanova D., Lehmann S. 2000; Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 74:3135–3140 [CrossRef]
    [Google Scholar]
23. May B. C., Fafarman A. T., Hong S. B., Rogers M., Deady L. W., Prusiner S. B., Cohen F. E. 2003; Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci U S A 100:3416–3421 [CrossRef]
    [Google Scholar]
24. Meyer R. K., McKinley M. P., Bowman K. A., Braunfeld M. B., Barry R. A., Prusiner S. B. 1986; Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A 83:2310–2314 [CrossRef]
    [Google Scholar]
25. Nishida N., Tremblay P., Sugimoto T. 12 other authors 1999; A mouse prion protein transgene rescues mice deficient for the prion protein gene from Purkinje cell degeneration and demyelination. Lab Invest 79:689–697
    [Google Scholar]
26. Nishida N., Harris D. A., Vilette D., Laude H., Frobert Y., Grassi J., Casanova D., Milhavet O., Lehmann S. 2000; Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J Virol 74:320–325 [CrossRef]
    [Google Scholar]
27. Nishikawa K., Matsuoka K., Kita E. 12 other authors 2002; A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157 : H7. Proc Natl Acad Sci U S A 99:7669–7674 [CrossRef]
    [Google Scholar]
28. Padilla De Jesus O. L., Ihre H. R., Gagne L., Frechet J. M., Szoka F. C. Jr 2002; Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 13:453–461 [CrossRef]
    [Google Scholar]
29. Priola S. A., Caughey B. 1994; Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. Mol Neurobiol 8:113–120 [CrossRef]
    [Google Scholar]
30. Priola S. A., Raines A., Caughey W. S. 2000; Porphyrin and phthalocyanine anti-scrapie compounds. Science 287:1503–1506 [CrossRef]
    [Google Scholar]
31. Prusiner S. B. 1982; Novel proteinaceous infectious particles cause scrapie. Science 216:136–144 [CrossRef]
    [Google Scholar]
32. Sethi S., Lipford G., Wagner H., Kretzschmar H. 2002; Post-exposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360:229–230 [CrossRef]
    [Google Scholar]
33. Supattapone S., Nguyen H. O., Cohen F. E., Prusiner S. B., Scott M. R. 1999; Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 96:14529–14534 [CrossRef]
    [Google Scholar]
34. Vincent L., Varet J., Pille J. Y. 9 other authors 2003; Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. Int J Cancer 105:419–429 [CrossRef]
    [Google Scholar]
35. Will R. G., Ironside J. W., Zeidler M. 7 other authors 1996; A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921–925 [CrossRef]
    [Google Scholar]